Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : INCY crawled time : 03:00 save search
Innovent Announces the Preclinical Results of IBI363 (PD-1/IL-2 Bispecific Antibody Fusion Protein) were Published in Nature Cancer
Published: 2023-08-08 (Crawled : 03:00) - prnewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.09%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 2.58%
H: 0.41%
C: -1.13%
ibi363 antibody cancer preclinical results
FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia Areata
Published: 2022-06-14 (Crawled : 03:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.49%
H: 0.98%
C: 0.56%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -2.09%
H: 0.41%
C: -1.96%
olumiant fda
FDA Advisory Committee Votes to Recommend Additional Data for Sintilimab Submission
Published: 2022-02-11 (Crawled : 03:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.09%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.74%
H: 0.0%
C: 0.0%
fda submission
Bijoyesh Mookerjee, M.D. named Chief Medical Officer, Oncology for Simcere Pharmaceuticals
Published: 2022-02-08 (Crawled : 03:00) - prnewswire.com
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -3.59%
H: 0.0%
C: 0.0%
als yes
Innovent Announces Inclusion of the Company's Stock (01801.HK) in the Hang Seng China Enterprises Index
Published: 2021-11-22 (Crawled : 03:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -1.61%
H: 0.67%
C: -0.68%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -1.1%
H: 0.22%
C: -1.92%
china
Innovent Releases the ORIENT-31 Phase 3 Study First Interim Analysis Results of Sintilimab plus BYVASDA (bevacizumab biosimilar injection) and Chemotherapy in Patients with EGFR-mutated Nonsquamous Non-small Cell Lung Cancer who Progressed After EGFR-TKI Therapy at ESMO Virtual Plenary 2021
Published: 2021-11-22 (Crawled : 03:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -1.61%
H: 0.67%
C: -0.68%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -1.1%
H: 0.22%
C: -1.92%
lung cancer therapy injection results cancer phase 3 biosimilar
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.